ABSTRACT
Importance People in prison are particularly vulnerable to infectious disease due to close living conditions and the lack of protective equipment. Public health professionals and prison administrators seek information to guide best practices regarding prison population to capacity rates for the COVID-19 outbreak.
Objective Using latent profile analysis, we sought to characterize Texas prisons on levels of COVID-19 cases and deaths among incarcerated residents, and COVID-19 cases among prison staff.
Design This observational study was a secondary data analysis of publicly available data from the Texas Department of Criminal Justice (TBDJ). Data were downloaded and analyzed on July 24, 2020. This project was completed in collaboration with the COVID Prison Project.
Setting One-hundred and three prisons in the state of Texas.
Participants The unit of analysis is the individual prison units that comprise the TDCJ.
Exposures None
Main Outcomes and Measures Latent profiles on levels of incarcerated resident COVID-19 cases, staff COVID-19 cases, and incarcerated resident COVID-19 deaths.
Results We identified relevant profiles from the data: a low outbreak profile, a high outbreak profile, and a high death profile. Additionally, current prison population and level of employee staffing predicted membership in the high outbreak and high death profiles when compared to the low outbreak profile.
Conclusions and Relevance Housing persons at 85% of prison capacity may minimize the risk of infection and death related to COVID-19. Implementing this 85% standard as an absolute minimum should be prioritized at prisons across the US.
Question Is there a population to capacity ratio for prisons to successfully reduce the number of COVID-19 infections and deaths among its incarcerated populations?
Findings The prisons that were most effective in reducing prison outbreaks and deaths operated at 85% of their current capacity.
Meaning Prisons should operate at 85% of capacity or less to successfully minimize the harmful effects of COVID-19 on incarcerated populations.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding: Dr. Vest was supported by the National Institute on Drug Abuse of the National Institutes of Health under Award Number T32DA035165; The COVID Prison Project is funded by the Langeloth Foundation
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Because the data was publicly available, it did not require approval from the University Institutional Review Board.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
These data are publically available from the COVID Prison Project and available from the authors on request.
